DELCATH SYSTEMS, INC. (DCTH) Form 8-K — Nov 9, 2026
Delcath Systems reported Q3 2026 revenue of $35.1 million, up 71% from $20.6 million in the prior-year quarter, driven by $32.7 million in HEPZATO KIT sales in the U.S. and $2.4 million in CHEMOSAT sales in Europe. Net income rose to $7.0 million from $0.8 million, with adjusted EBITDA of $11.5 million and gross margins of 89%. The company raised its full-year 2026 revenue guidance to $115-117 million, reflecting at least 41% growth in HEPZATO volume over 2025, and now holds $104.3 million in cash and investments with no debt.
Key figures
- Eps
- 0.19
- Revenue
- 35100000
- Guidance
- 2026 total HEPZATO KIT and CHEMOSAT revenue of $115-117 million, HEPZATO volume growth of at least 41% over 2025, gross margins 87-89%, positive adjusted EBITDA
- Total Debt
- 0
- Revenue Yoy
- 71%
- Total Assets
- 149090000
- Cash Position
- 104300000
- Shares Outstanding
- 34771239
- Basic eps
- $0.19
- Diluted eps
- $0.17
- Gross margin q3
- 89%
- Adjusted ebitda q3
- 11500000
- Hepzato revenue q3
- 32700000
- Chemosat revenue q3
- 2400000
- Hepzato volume growth
- ~72% YoY
- Prior year q3 revenue
- 20600000
- Operating cash flow q3
- 8200000
- Active treatment centers
- 33
- Prior year q3 net income
- 830000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.